1. Clinical Overview
Hemocoagulase is a hemostatic agent derived from the venom of the Bothrops atrox snake. It is a complex of two main enzymes: thrombin-like enzyme (TLE) and Factor X activator. It acts locally to promote clot formation at the site of bleeding without causing systemic hypercoagulability, making it a valuable agent for controlling capillary and venous bleeding in surgical and traumatic settings. In India, it is widely used across surgical specialties.
| Onset | Duration | Bioavailability |
|---|---|---|
| Hemostasis typically begins within 5-10 minutes of topical application or local injection. | The local hemostatic effect lasts for 12-24 hours, sufficient for initial clot stabilization. | Not applicable (NA) for systemic use as it is intended for topical/local administration. Systemic absorption is negligible. |
2. Mechanism of Action
Hemocoagulase exerts its hemostatic action through two synergistic pathways: 1) Thrombin-like Enzyme (TLE): Directly converts fibrinogen to fibrin monomers, forming a stable clot. Unlike thrombin, TLE is not inhibited by antithrombin III. 2) Factor X Activator: Activates Factor X to Factor Xa, which in turn, along with Factor V, converts prothrombin to thrombin, amplifying the clotting cascade. This dual action leads to rapid, localized fibrin clot formation without depleting systemic clotting factors or causing significant systemic thrombosis.
3. Indications & Uses
- Control of capillary and venous bleeding in various surgical procedures (e.g., ENT, Dental, Ophthalmic, General, Orthopedic, Plastic Surgery)
- Management of traumatic wounds with diffuse oozing
- Epistaxis (Nosebleeds) management when topical application is feasible
4. Dosage & Administration
Adult Dosage: Dose is highly dependent on the extent of bleeding and surgical site. Typical dose: 1-2 IU (International Units) by local injection (submucosal, subserosal) or topical application (soaked in sterile gauze). May be repeated if necessary. Always follow specific brand prescribing information.
Administration: For INJECTION: Reconstitute with provided solvent (usually 1-2 ml of sterile water/NS). Inject slowly into the tissue surrounding the bleeding site or into the submucosa/subserosa. Do NOT inject intravenously or intra-arterially. For TOPICAL USE: Apply solution directly to the bleeding surface or soak a sterile gauze piece and apply under pressure for several minutes.
5. Side Effects
Common side effects may include:
- Mild pain or burning sensation at the injection/application site
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Anticoagulants (Warfarin, DOACs) | Hemocoagulase's local hemostatic effect may be reduced in systemically anticoagulated patients. No direct pharmacokinetic interaction. | Moderate |
| Antiplatelets (Aspirin, Clopidogrel) | May reduce efficacy of hemocoagulase for controlling bleeding. No direct interaction. | Moderate |
| Thrombolytics (Streptokinase, Alteplase) | Concurrent use is contradictory. Thrombolytics may lyse the clot formed by hemocoagulase. | Major |
7. Patient Counselling
- Do inform your doctor about any allergy to medicines or snake bites.
- Do report any history of blood clots (DVT, stroke) to your doctor before a procedure where this may be used.
- This medicine is administered by a healthcare professional in a controlled setting; patients do not self-administer.
8. Toxicology & Storage
Overdose: Systemic overdose is unlikely with proper local use. Theoretical symptoms with massive local dose or IV injection could include signs of thrombosis (pain, swelling, redness in limbs, shortness of breath) or, paradoxically, a consumptive coagulopathy.
Storage: Store in a refrigerator (2°C to 8°C). Do not freeze. Protect from light. Keep the vial in the outer carton. After reconstitution, use immediately. Discard any unused solution.